Related Experiment Video

Updated: Feb 8, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

4.3K

Contemporary Septal Reduction Therapy in Drug-Refractory Hypertrophic Obstructive Cardiomyopathy

Yuichiro Maekawa1, Keitaro Akita1, Shuichiro Takanashi2

  • 1Internal Medicine III, Hamamatsu University School of Medicine.

Circulation Journal : Official Journal of the Japanese Circulation Society
|June 19, 2018
PubMed

Insights

Hypertrophic cardiomyopathy (HCM) can cause obstructive symptoms requiring septal reduction therapy (SRT). This review explores SRT, including surgical myectomy and percutaneous transluminal septal myocardial ablation (PTSMA), for managing HCM.

Area of Science:

  • Cardiology
  • Genetics
  • Cardiac Surgery

Background:

  • Hypertrophic cardiomyopathy (HCM) is a common genetic heart disease.
  • Many HCM patients are asymptomatic, but some develop left ventricular hypertrophy and obstructive symptoms over time.
  • Symptoms can worsen despite medical management, necessitating interventions.

Purpose of the Study:

  • To review the emerging concept and practical implications of septal reduction therapy (SRT) for HCM.
  • To evaluate the evidence for percutaneous transluminal septal myocardial ablation (PTSMA) and surgical myectomy in the literature.

Main Methods:

  • Literature review focusing on SRT in hypertrophic cardiomyopathy.
  • Analysis of evidence for PTSMA and surgical myectomy.

Main Results:

  • Septal reduction therapy (SRT) is a key treatment for symptomatic obstructive HCM.
  • Both PTSMA and surgical myectomy are established SRT options.
  • Evidence on the comparative effectiveness and outcomes of PTSMA versus surgical myectomy is discussed.

Conclusions:

  • SRT is crucial for managing worsening obstructive symptoms in HCM.
  • The choice between PTSMA and surgical myectomy depends on various factors and available evidence.
  • Further research may refine treatment strategies for HCM.

Keywords:
Heart failureHypertrophic cardiomyopathySeptal reduction therapy

More Related Videos

Reduction of Iatrogenic Atrial Septal Defects with an Anterior and Inferior Transseptal Puncture Site when Operating the Cryoballoon Ablation Catheter08:00

Reduction of Iatrogenic Atrial Septal Defects with an Anterior and Inferior Transseptal Puncture Site when Operating the Cryoballoon Ablation Catheter

Published on: June 15, 2015

14.5K
A Mouse Model of Mechanotransduction-driven, Human-like Hypertrophic Scarring05:54

A Mouse Model of Mechanotransduction-driven, Human-like Hypertrophic Scarring

Published on: November 29, 2024

2.2K

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
509
Drug Therapy01:28

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
302
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
575
Contemporary Psychology01:29

Contemporary Psychology

Psychology explores human behavior and mental processes through various lenses, each offering unique insights. This overview examines key subfields, including biopsychology, evolutionary, developmental, personality, and social psychology, highlighting their approaches and contributions to understanding complex human behaviors.
Biopsychology
Biopsychology, also known as biological psychology or behavioral neuroscience, focuses on the biological underpinnings of behavior and mental processes. It...
2.3K
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
575
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.4K